Results 91 to 100 of about 16,299 (214)
Journal of Applied Toxicology, EarlyView.ABSTRACT One of the most serious complications associated with the use of the chemotherapeutic agent doxorubicin (DOX) is cardiomyopathy. Although cardioprotective drugs such as angiotensin receptor‐neprilysin inhibitors (ARNI) are used to prevent cardiomyopathy in DOX patients, no studies have reported the relationship between ARNI and endoplasmic ...
Mert Unvan +3 more
wiley +1 more source
Broadening the View: Substance P and Its Metabolism in Pruritus‐Related Diseases
The Journal of Dermatology, EarlyView.ABSTRACT Chronic pruritus is a debilitating symptom accompanying numerous inflammatory skin diseases and remains a major therapeutic challenge. Neurogenic inflammation plays a central role in its pathogenesis, with the tachykinin substance P acting as a key mediator at the interface of the nervous system, immune cells, and cutaneous tissues.
Thomas Walter, Bjoern B. Burckhardt
wiley +1 more source
PharmaceuticsBackground/Objectives: Radiotheranostics of neurotensin subtype 1 receptor (NTS1R)-expressing tumors, like pancreatic, gastrointestinal, or prostate cancer, has attracted considerable attention in recent years. Still, the fast degradation of neurotensin (
Panagiotis Kanellopoulos +3 more
doaj +1 more source
Allergy, EarlyView.ABSTRACT This update and revision of the international guideline for urticaria was developed in accordance with the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is an initiative of the Global Allergy and Asthma Excellence Network (GA2LEN) and its Urticaria and ...
T. Zuberbier +221 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Hypertension and diabetes frequently coexist, yet the net clinical impact of intentionally combining antihypertensive (AHTN) and antidiabetic (ADA) therapies on cardiovascular (CV) outcomes is uncertain. Here we quantified the effects of AHTN and ADA co‐therapy on CV and blood pressure (BP)/heart rate (HR) outcomes.
Wan Chin Hsieh +2 more
wiley +1 more source
Internal Medicine Journal, EarlyView.Abstract Background Sodium‐glucose co‐transporter 2 inhibitors (SGLT2is) improve symptoms, reduce hospitalisations and increase survival in patients with heart failure with reduced ejection fraction (HFrEF). This study evaluated SGLT2i prescribing compliance in hospitalised patients with HFrEF at an Australian tertiary hospital.
Salim Memon +4 more
wiley +1 more source
Journal of Cardiovascular Electrophysiology, EarlyView.Left bundle branch area pacing is associated with preservation of ventricular function in patients with bradycardia indications and with significant reverse remodeling and symptomatic improvement in patients with heart failure. Maintaining a high percentage of effective LBBAP capture is critical to minimize the risk of pacing‐induced cardiomyopathy and
Gabriele Dell'Era +32 more
wiley +1 more source
Journal of Diabetes Investigation, EarlyView.ABSTRACT Preclinical heart failure (HF) (stages A and B) is common but easily overlooked in asymptomatic patients with type 2 diabetes (T2D). There is a paucity of evidence regarding how coexisting risk factors contribute to the development of HF in asymptomatic Asian patients with T2D, and there is a lack of guidance on the early identification of ...
Jiun‐Lu Lin +9 more
wiley +1 more source
Journal of Diabetes Investigation, EarlyView.SGLT2 inhibitor use at discharge was associated with a reduced risk of heart failure readmission in elderly patients with diabetes, with no significant differences among individual agents. ABSTRACT Aims To evaluate the effect of sodium–glucose cotransporter 2 inhibitor (SGLT2i) administration at hospital discharge on heart failure (HF) readmission ...
Kazuya Hiura +3 more
wiley +1 more source